Evidence map›Paper›PMID 25117407›Full record

ArticleAmerican journal of physiology. Endocrinology and metabolism2014

Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium.

Megan DeNicola, Jianfeng Du, Zhengke Wang, Naohiro Yano, Ling Zhang, Yigang Wang, Gangjian Qin, Shougang Zhuang, Ting C Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of physiology. Endocrinology and metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 60 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Glucagon-like peptide-1 receptor expression after myocardial infarction: Imaging study usingJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2020
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Megan DeNicolaDepartment of Surgery, Roger Williams Medical Center, Boston University Medical School, Boston University, Providence, Rhode Island;
Jianfeng DuDepartment of Surgery, Roger Williams Medical Center, Boston University Medical School, Boston University, Providence, Rhode Island;
Zhengke WangDepartment of Surgery, Roger Williams Medical Center, Boston University Medical School, Boston University, Providence, Rhode Island;
Naohiro YanoDepartment of Obstetrics and Gynecology, Women and Infants' Hospital of Rhode Island, Providence, Rhode Island;
Ling ZhangDepartment of Emergency.
Yigang WangDepartment of Pathology and Laboratory Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio; and.
Gangjian QinFeinberg Cardiovascular Research Institute, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Shougang ZhuangDepartment of Medicine, Rhode Island Hospital, Alpert Medical School, Brown University, Providence, Rhode Island;
Ting C ZhaoDepartment of Surgery, Roger Williams Medical Center, Boston University Medical School, Boston University, Providence, Rhode Island; tzhao@bu.edu.
Roger Williams Medical Center · USBoston University · USNorthwestern University · USProvidence College · USRhode Island Hospital · USUniversity of Cincinnati Medical Center · USWomen & Infants Hospital of Rhode Island · US

Funding

Histone Deacetylase Inhibition: A Novel Approach to CardioprotectionR01HL089405 · NHLBI · ROGER WILLIAMS MEDICAL CENTER · PI ZHAO, TING C · 2009 to 2020
$3.4M
p38 acetylation: Novel signaling mechanisms and myocardial protectionR01HL115265 · NHLBI · ROGER WILLIAMS MEDICAL CENTER · PI ZHAO, TING C · 2013 to 2016
$1.6M
NHLBI NIH HHS R01 HL089405NHLBI NIH HHS R01-HL-089405NHLBI NIH HHS R01 HL115265NHLBI NIH HHS R01-HL-115265
6 · The paper itself

Abstract

We have demonstrated that GLP-1 improved myocardial functional recovery in acute myocardial ischemic injury. However, whether stimulation of the GLP-1 receptor (GLP-1R) with exendin-4, a selective GLP-1R agonist, could initiate a protective effect in the heart remains to be determined. Mouse myocardial infarction (MI) was created by ligation of the left descending artery. After 48 h of MI, animals were divided into the following groups (n = 5-7/group): 1) sham (animals that underwent thoracotomy without ligation), 2) MI [animals that underwent MI and received a daily dose of intraperitoneal injection (ip) of saline]; and 3) MI + exendin-4 [infarcted mice that received injections of exendin-4 (0.1 mg/kg ip)]. Two weeks later, cardiac function was assessed by echocardiography and an isovolumetrically perfused heart. Compared with control MI hearts, stimulation of GLP-1R improved cardiac function, which was associated with attenuation of myocardial hypertrophy, the mitigation of interstitial fibrosis, and an increase in survival rate in post-MI hearts. Furthermore, H9c2 cardiomyoblasts were preconditioned with exendin-4 at a dose of 100 nmol/l and then subjected to hydrogen peroxide exposure at concentrations of 50 and 100 μmol/l. The exendin-4 treatment decreased lactate dehydrogenase leakage and increased cell survival. Notably, this event was also associated with the reduction of cleaved caspase-3 and caspase-9 and attenuation of reactive oxygen species production. Exendin-4 treatments improved mitochondrial respiration and suppressed the opening of mitochondrial permeability transition pore and protected mitochondria function. Our results indicate that GLP-1R serves as a novel approach to eliciting cardioprotection and mitigating oxidative stress-induced injury.

Indexed as

Disease Models, AnimalAnimalsAntioxidantsApoptosisCardiotonic AgentsCell LineCell SurvivalExenatideGlucagon-Like Peptide-1 ReceptorHeart VentriclesHypertrophy, Left VentricularKaplan-Meier EstimateMaleMice, Inbred ICRMitochondria, HeartMolecular Targeted TherapyAntioxidantsCardiotonic AgentsExenatideGlp1r protein, mouseGlp1r protein, ratGlucagon-Like Peptide-1 ReceptorPeptidesReceptors, GlucagonVenomsexendin-4glucagon-like peptide-1 receptorheartinfarctionoxidant stress

Identifiers

PMID25117407
PMCPMC4200306
OpenAlexW2042282560

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.